{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:14:15Z","timestamp":1788444855091,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA015831"],"award-info":[{"award-number":["UG1DA015831"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The initiation of buprenorphine for patients with opioid use disorder (OUD) in the emergency department (ED) has been associated with improved outcomes including reduced ED visits and increased treatment engagement. Though both standard-dose (8\u2009mg buprenorphine equivalent) and high-dose (24\u2009mg buprenorphine equivalent) strategies to initiate buprenorphine have been used in the ED, no prospective trials comparing outcomes among patients receiving these treatments have been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multisite randomised clinical trial is a multisite double-blind, double-dummy, randomised clinical trial enrolling 360 emergency department patients with moderate-to-severe OUD. Enrolled patients will be randomised to one of two study arms: standard-dose induction or high-dose induction, both provided in the ED. This study will engage, train and provide resources to five EDs throughout the US to recruit patients with untreated OUD into a randomised clinical trial. The primary aim is to evaluate the effects of the standard-dose induction and high-dose induction on rates of OUD treatment participation within 10 days post-randomisation. The secondary aims are to evaluate differences between standard-dose induction and high-dose induction on the outcomes of opioid craving, opioid withdrawal symptoms and illicit drug use assessed during 10 days post randomisation and evaluate the effects between treatment arms on rates of OUD treatment participation within 30 days post randomisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study is funded by the National Institute on Drug Abuse and has been approved by the WCG Instutitional Review Board. It has been registered at clinicaltrials.gov. This study will inform the strategy for treatment initiation with buprenorphine among diverse ED settings and will provide ongoing evidence to support the safety and efficacy of initiating treatment for OUD in the ED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06494904\">NCT06494904<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-113762","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:05:37Z","timestamp":1780502737000},"page":"e113762","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Emergency Department-initiated standard versus high-dose buprenorphine induction (ENVISION): a randomised clinical trial protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06494904","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5945","authenticated-orcid":false,"given":"Kathryn","family":"Hawk","sequence":"first","affiliation":[{"name":"Department of Emerency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Herring","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Highland Hospital, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Chawarski","sequence":"additional","affiliation":[{"name":"Department of Emerency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Highland Hospital, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Maine Medical Center, Portland, Maine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyrene","family":"Dorey","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August F","family":"Holtyn","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse Clinical Trials Network, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-9094","authenticated-orcid":false,"given":"Christopher","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shara","family":"Martel","sequence":"additional","affiliation":[{"name":"Department of Emerency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Emerency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Kmiecik","sequence":"additional","affiliation":[{"name":"The Emmes Corporation, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania D.","family":"Strout","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Maine Medical Center, Portland, Maine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Taillac","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Utah School of Medicine, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lofwall","sequence":"additional","affiliation":[{"name":"Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Department of Emerency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026090306262866000_16.6.e113762.1","doi-asserted-by":"crossref","unstructured":"Provisional County-Level Drug Overdose Death Counts. 2025. doi:10.15620\/cdc\/20250305009","DOI":"10.15620\/cdc\/20250305009"},{"key":"2026090306262866000_16.6.e113762.2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026090306262866000_16.6.e113762.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9345157.x"},{"key":"2026090306262866000_16.6.e113762.4","unstructured":"Center for Behavioral Health Statistics S . Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health, Available: https:\/\/library.samhsa.gov"},{"key":"2026090306262866000_16.6.e113762.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1811988"},{"key":"2026090306262866000_16.6.e113762.6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.annemergmed.2012.02.003","article-title":"Alcohol and drug use disorders among adults in emergency department settings in the United States","volume":"60","author":"Wu","year":"2012","journal-title":"Ann Emerg Med"},{"key":"2026090306262866000_16.6.e113762.7","unstructured":"Yeboah-Sampong S , Weber E , Friedman S . EMERGENCY: Hospitals Are Violating Federal Law by Denying Required Care for Substance Use Disorders in Emergency Departments, 2021. Available: www.lac.org\/page\/reproduction-distribution"},{"key":"2026090306262866000_16.6.e113762.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.04.020"},{"key":"2026090306262866000_16.6.e113762.9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.annemergmed.2021.04.023","article-title":"Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department","volume":"78","author":"Hawk","year":"2021","journal-title":"Ann Emerg Med"},{"key":"2026090306262866000_16.6.e113762.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1572","article-title":"High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids","volume":"6","author":"Snyder","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026090306262866000_16.6.e113762.11","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2011.642758"},{"key":"2026090306262866000_16.6.e113762.12","unstructured":"California ED Bridge, Available: https:\/\/cabridge.org"},{"key":"2026090306262866000_16.6.e113762.13","unstructured":"NIDA . Initiating Buprenorphine in the Emergency Department, 2017. Available: https:\/\/nida.nih.gov\/nidamed-medical-health-professionals\/discipline-specific-resources\/emergency-physicians-first-responders\/initiating-buprenorphine-treatment-in-emergency-department"},{"key":"2026090306262866000_16.6.e113762.14","unstructured":"Yale . ED-Initated Buprenorphine, Available: https:\/\/medicine.yale.edu\/edbup\/"},{"key":"2026090306262866000_16.6.e113762.15","unstructured":"BUP Initation App, 2021. Available: https:\/\/apps.apple.com\/us\/app\/bup-initiation\/id1574350314#?platform=iphone"},{"key":"2026090306262866000_16.6.e113762.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"2026090306262866000_16.6.e113762.17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/ADM.0000000000000060","article-title":"Clinical case conference: unobserved \u201chome\u201d induction onto buprenorphine","volume":"8","author":"Lee","year":"2014","journal-title":"J Addict Med"},{"key":"2026090306262866000_16.6.e113762.18","unstructured":"FDA Website . Buprenrophine Drug Label (Suboxone). 2002. Available: https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM191529.pdf"},{"key":"2026090306262866000_16.6.e113762.19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.53771","article-title":"Emergency Department Access to Buprenorphine for Opioid Use Disorder","volume":"7","author":"Herring","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026090306262866000_16.6.e113762.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00270-X"},{"key":"2026090306262866000_16.6.e113762.21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026090306262866000_16.6.e113762.22","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001189"},{"key":"2026090306262866000_16.6.e113762.23","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746110-00004"},{"key":"2026090306262866000_16.6.e113762.24","doi-asserted-by":"crossref","DOI":"10.1002\/emp2.12606","article-title":"Emergency department-initiated buprenorphine protocols: A national evaluation","volume":"2","author":"Guo","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2026090306262866000_16.6.e113762.25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/03639045.2013.846365","article-title":"Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine\/naloxone tablet formulation in healthy volunteers","volume":"41","author":"Fischer","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"key":"2026090306262866000_16.6.e113762.26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/acem.14197","article-title":"A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs","volume":"28","author":"Hawk","year":"2021","journal-title":"Acad Emerg Med"},{"key":"2026090306262866000_16.6.e113762.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44955","article-title":"Perspectives About Emergency Department Care Encounters Among Adults With Opioid Use Disorder","volume":"5","author":"Hawk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026090306262866000_16.6.e113762.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.20661","article-title":"Racial and Ethnic Factors and Opioid Use Disorder Treatment After an Emergency Department Visit","volume":"8","author":"Coupet","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026090306262866000_16.6.e113762.29","doi-asserted-by":"crossref","first-page":"106359","DOI":"10.1016\/j.cct.2021.106359","article-title":"The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation","volume":"104","author":"D\u2019Onofrio","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"2026090306262866000_16.6.e113762.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.04.006"},{"key":"2026090306262866000_16.6.e113762.31","doi-asserted-by":"crossref","unstructured":"Sobell L , Sobell M . Measuring alcohol consumption: psychosocial and biological methods. Humana Press, 1992:41\u201372.","DOI":"10.1007\/978-1-4612-0357-5_3"},{"key":"2026090306262866000_16.6.e113762.32","unstructured":"Alan A . Categorical data analysis. Wiley, 2013. Available: https:\/\/www.amazon.com\/Categorical-Data-Analysis-Alan-Agresti\/dp\/0470463635"},{"key":"2026090306262866000_16.6.e113762.33","unstructured":"Jrlka W . Modeling binary correlated responses using SAS, SPSS and R. Springer International PU, 2016. Available: https:\/\/koha.ista.ac.at\/cgi-bin\/koha\/opac-detail.pl?biblionumber=371810"},{"key":"2026090306262866000_16.6.e113762.34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.3.310"},{"key":"2026090306262866000_16.6.e113762.35","unstructured":"Stroup W , George M , Claassen E , et al . SAS system for mixed models: introduction and basic applications. SAS Institute Inc, 2018."},{"key":"2026090306262866000_16.6.e113762.36","doi-asserted-by":"publisher","DOI":"10.1890\/13-1452.1"},{"key":"2026090306262866000_16.6.e113762.37","doi-asserted-by":"crossref","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences. Routledge, 2013. Available: https:\/\/www.taylorfrancis.com\/books\/9781134742707","DOI":"10.4324\/9780203771587"},{"key":"2026090306262866000_16.6.e113762.38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jsat.2013.08.020","article-title":"Psychometric properties of the adjective rating scale for withdrawal across treatment groups, gender, and over time","volume":"46","author":"Barbosa-Leiker","year":"2014","journal-title":"J Subst Abuse Treat"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-113762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:27:48Z","timestamp":1788442068000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-113762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjopen-2025-113762"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-113762","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}